CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 5, 2019-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that on November 1, 2019 , the

  CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 9, 2019-- Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced it will host a live webcast on

  CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 2, 2019-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that on October 1, 2019 ,

  Enrollment complete in the Phase 3 MOUNTAIN Study evaluating SAGE-217 in the treatment of major depressive disorder (MDD); topline results expected in 4Q 2019     CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 2, 2019-- Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company committed to

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 5, 2019-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that on September 3, 2019 ,

Results from pivotal trial showed treatment with SAGE-217 resulted in rapid, clinically meaningful improvement in major depressive disorder (MDD) symptoms across multiple measures and time points SAGE-217 is currently being investigated in the Phase 3 MOUNTAIN trial for the treatment of MDD, with

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 3, 2019-- Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present at the

ZULRESSO™ (brexanolone) injection CIV, the first treatment specifically indicated for postpartum depression, commercially launched in the U.S. in late-June, with first patients treated in July 2019 Commercial execution is progressing as expected and on-track across key focus areas including

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 5, 2019-- Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will participate in

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 5, 2019-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that on August 1, 2019 , the